Full Prescribing Information, Including BOXED WARNING
Read About Twirla
Agile Therapeutics to Present at Upcoming March Investor Conferences
Agile Therapeutics Reports Fourth Quarter & Full Year 2020 Financial Results; Expands Loan Facility With Perceptive Advisors
Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on Monday, March 1, 2021
Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
Agile Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Agile Therapeutics Announces Nationwide Commercial Launch and Availability of Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System, a New Non-Daily, Non-Invasive Contraceptive Patch
Agile Therapeutics Announces Peer-Reviewed Publication of Phase 3 SECURE Study Results for Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System in Contraception
Agile Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
Agile Therapeutics Reports Third Quarter 2020 Financial Results
Our pipeline reflects our commitment to bringing women the healthcare choices they deserve. All current Agile Therapeutics product and product candidates use our proprietary Skinfusion® Technology.
Commitment. Passion. Drive.
These are the qualities that make us who we are, from the top down.
©2020 Agile Therapeutics®. All Rights Reserved.